• Primidone (Mysoline): Dual Targeting for Translational Innov

  2026-04-30

  This article delivers a mechanistic and strategic deep-dive into Primidone (Mysoline) as a dual TRPM3 and RIPK1 inhibitor, focusing on actionable insights for translational researchers. Integrating cryo-EM revelations, validated dosing strategies, and cross-model applications, it bridges foundational biology with protocol-level guidance—positioning APExBIO’s Primidone at the forefront of neurodevelopmental and neurodegenerative research.

• SU 5402: Precision RTK Inhibition in Translational Oncology

  2026-04-30

  This thought-leadership article delves into SU 5402’s mechanistic power as a multi-targeted receptor tyrosine kinase inhibitor and its strategic value for translational researchers in cancer biology and neuronal disease. It bridges robust preclinical insights with actionable protocol guidance, highlighting SU 5402’s differentiation from standard RTK inhibitors, and referencing both peer-reviewed findings and emerging stem cell-neuronal models.

• Thioredoxin 1 Modulates Lens Iron Metabolism in Oxidative Ca

  2026-04-29

  This study identifies thioredoxin 1 (Trx1) as a key regulator of iron metabolism and antioxidant recovery in the late stages of oxidative damage in lens tissue, relevant to age-related cataract. The findings suggest Trx1 and related pathways as promising targets for developing non-surgical interventions against cataract progression.

• G007-LK Tankyrase 1/2 Inhibitor: Precision Tool for β-Cateni

  2026-04-29

  Explore how G007-LK, a potent tankyrase 1/2 inhibitor, enables rigorous modulation of Wnt/β-catenin and Hippo signaling for advanced APC mutation colorectal cancer research. Uncover unique insights on pathway crosstalk and assay optimization not found in other reviews.

• Mitochondrial Calcium Regulates Ferroptosis via GPX4 Acetyla

  2026-04-28

  This study uncovers a direct mechanistic link between mitochondrial calcium signaling, mediated by the mitochondrial calcium uniporter (MCU), and repression of ferroptotic cell death through GPX4 acetylation. The findings highlight the essential role of mitochondrial metabolism in controlling ferroptosis and suggest new directions for targeted intervention in disease models where ferroptosis is implicated.

• Anti Reverse Cap Analog: Enhancing Synthetic mRNA Translatio

  2026-04-28

  Unlock superior translational efficiency and mRNA stability with Anti Reverse Cap Analog (ARCA), 3´-O-Me-m7G(5')ppp(5')G. This guide demystifies advanced workflows, troubleshooting, and pivotal research applications, empowering scientists to engineer potent synthetic mRNAs for cutting-edge therapeutics and cellular reprogramming.

• Pharmacokinetics of CSBTA in MASH: PXR and CYP3A Pathway Ins

  2026-04-27

  This study investigates how metabolic dysfunction-associated steatohepatitis (MASH) alters the pharmacokinetics and tissue distribution of key alkaloids from Corydalis saxicola Bunting. It reveals that pathological liver states modulate drug metabolism via cytochrome P450 enzymes and PXR-regulated transporters, guiding future MASLD/MASH therapy optimization.

• 12-O-tetradecanoyl phorbol-13-acetate: Benchmarks in ERK/MAP

  2026-04-27

  12-O-tetradecanoyl phorbol-13-acetate (TPA) is a robust activator of ERK/MAPK and protein kinase C pathways, indispensable for signal transduction research. APExBIO’s TPA (N2060) enables reproducible in vitro and in vivo modeling, particularly in skin carcinogenesis and kinase activation studies.

• 3D Tumor Spheroid Assay for Detecting Glioblastoma Stemness

  2026-04-26

  This study introduces a streamlined 3D-tumor spheroid assay to evaluate the stemness of glioblastoma cell lines, reducing time and contamination risk compared to traditional methods. The protocol supports high-throughput screening and mechanistic studies targeting glioma stem-like cells, with significant implications for preclinical research and drug development.

• Solving Cell Assay Challenges with (-)-Blebbistatin (SKU B13

  2026-04-25

  This article provides an evidence-based, scenario-driven analysis of how (-)-Blebbistatin (SKU B1387) enables robust, reproducible results in cell viability, proliferation, and cytotoxicity workflows. Drawing on peer-reviewed data and validated protocols, it equips biomedical researchers and laboratory personnel to navigate common experimental pitfalls and optimize actin-myosin interaction inhibition assays using APExBIO’s trusted reagent.

• Fasudil (HA-1077) HCl: Precision ROCK Inhibition in Cancer R

  2026-04-24

  Fasudil (HA-1077) HCl empowers researchers to dissect Rho/ROCK pathway dynamics with high selectivity and reproducibility, enabling nuanced studies of cell proliferation, migration, and apoptosis. This guide distills best-practice protocols, workflow innovations, and troubleshooting strategies to maximize data quality in disease models and advanced signaling research.

• Ciprofloxacin: Fluoroquinolone Antibiotic Mechanisms & Evide

  2026-04-24

  Ciprofloxacin is a synthetic fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, crucial for antimicrobial resistance research. High-purity formulations such as those from APExBIO enable reproducible laboratory assays and precise study of resistance gene transmission.

• Dronedarone (Multaq) in AF Research: Channel Selectivity and

  2026-04-23

  Explore the advanced pharmacological profile of Dronedarone (Multaq) in atrial fibrillation research. This article provides a deep dive into ion channel selectivity, practical assay insights, and evidence-based guidance distinct from standard product overviews.

• CLK2 Inhibition to Overcome Platinum Resistance in Ovarian C

  2026-04-23

  This study demonstrates that Cdc2-like kinase 2 (CLK2) drives platinum resistance in ovarian cancer by enhancing DNA repair through BRCA1 phosphorylation. Targeting CLK2 offers a mechanistically supported strategy to sensitize tumors to platinum chemotherapy and potentially improve patient outcomes.

• High-Throughput BBB Modeling: Integrating MDR1 Cells and Lys

  2026-04-22

  This study introduces a robust, high-throughput in vitro blood-brain barrier (BBB) model using LLC-PK1-MOCK and LLC-PK1-MDR1 cells, enhanced by lysosomal trapping correction. The model demonstrates high predictive accuracy for CNS drug permeability and offers a scalable tool for early-stage neuropharmaceutical research.

15217 records 1/1015 page Next 12345 下5页 Last page